A Study to Assess the Anti-Emetic Efficacy of Ginger in Children and Adolescents Receiving Chemotherapy
A Study to Evaluate the Anti-Emetic Effect of Ginger Powder Vs Placebo as an Add-on Therapy in Children and Adolescents Receiving Chemotherapy : A Randomized Controlled Trial
1 other identifier
interventional
60
1 country
1
Brief Summary
Ginger root powder is found to be significantly effective,when given as an add-on therapy in reducing chemotherapy induced nausea and vomiting in children and adolescents receiving chemotherapy. It is very cost effective and as compared to the other add-on therapy drug like aprepitant.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Jun 2009
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2009
CompletedFirst Submitted
Initial submission to the registry
July 15, 2009
CompletedFirst Posted
Study publicly available on registry
July 16, 2009
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2009
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2010
CompletedJuly 28, 2009
July 1, 2009
6 months
July 15, 2009
July 24, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Reduction in the Incidence and Severity of Chemotherapy Induced Nausea and Vomiting
6 months
Study Arms (2)
Ginger arm
EXPERIMENTALThe patients in this arm will be randomly selected in each cycle of chemotherapy. The unit of randomization is the cycle of chemotherapy. In each cycle of chemotherapy of all patients recruited in the study will be categorized using the computer generated random numbers. The patients in the ginger arm; Group A will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group A: Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram ginger powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram ginger powder per day
Placebo arm
PLACEBO COMPARATORPatients (children and adolescents) will be included in this arm after randomization of the cycle of chemotherapy of the patient. Starch powder/Glucose powder is used as placebo.The patients in the placebo arm; Group B will be getting ginger powder capsules according to their body weight;ie;there are two weight categories within Group B: Category 1- 20kg-40kg Category 2- 40kg-60kg Category 1 will receive 2 capsules 3 times a day,ie; 1gram placebo powder per day Category 2 will receive 5 capsule divided in 3 doses per day,ie; 2gram placebo powder per day
Interventions
The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy. For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram. For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram.
Eligibility Criteria
You may qualify if:
- All patients must have a histologically confirmed diagnosis of Osteosarcoma/ Malignant Fibrohistiocytoma of bone that is currently being treated with chemotherapy with high emetogenic potential chemotherapeutic agent(Cisplatin at a dose 120mg/m2 ; Adriamycin 75 mg/m2)
- Age group : 8-21 yrs.
- Weight : greater than or equal to 20 kg and less than 40 kg in Category 1
- Weight : greater than or equal to 40 kg and less than 60 kg in Category 2
- Patients who are willing to participate in study.
- Patients or their parents who can understand Hindi or English.
You may not qualify if:
- Patients of age \<8 yrs or age \>21 yrs.
- Weight \< 20 kg and greater than or equal to 40 kg in Category 1
- Weight \< 40 kg and greater than or equal to 60 kg in Category 2
- Patients receiving chemotherapy with drugs other than Cisplatin.
- Patients receiving a dosage of chemotherapy with Cisplatin\<120 mg/m2.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dr. B.R. Ambedkar Institute Rotary Cancer Hospital
New Delhi, National Capital Territory of Delhi, 110049, India
Related Publications (1)
Pillai AK, Sharma KK, Gupta YK, Bakhshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer. 2011 Feb;56(2):234-8. doi: 10.1002/pbc.22778. Epub 2010 Sep 14.
PMID: 20842754DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anu K, BSc.Nursing
All India Institute of Medical Sciences
- STUDY DIRECTOR
Kamlesh K Sharma, MSc.Nursing
All India Institute of Medical Sciences
- STUDY CHAIR
Sameer Bakhshi, MD
All India Institute of Medical Sciences
- STUDY CHAIR
Y K Gupta, MD,FAMS,FIPS
All India Institute of Medical Sciences
Central Study Contacts
Kamlesh K Sharma, MScNursing
CONTACT
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
July 15, 2009
First Posted
July 16, 2009
Study Start
June 1, 2009
Primary Completion
December 1, 2009
Study Completion
January 1, 2010
Last Updated
July 28, 2009
Record last verified: 2009-07